Navigation Links
Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
Date:3/19/2013

actice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com/. Follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described.  All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results.  Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K.  Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business.  Unless otherwise noted, Amgen is providing this information as of March 19, 2013 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ mat
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amgen Announces 2013 Second Quarter Dividend
2. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
3. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
4. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
5. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
6. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
7. Amgen Announces 2012 Third Quarter Dividend
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen to Acquire Micromet
10. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
11. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... ... A new host-based therapy for Ebola, anthrax and other ... and its collaborators. The discovery has the potential to speed to market treatments ... by Scientific Reports, an open access research journal from the publishers of Nature. ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... release of a groundbreaking new version of its flagship DNA design platform, which ... down complex DNA sequences into numerous genetic parts, which in turn can be ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Global Supply Chain ... management and resiliency practitioners with luminaries and thought leaders to advance the professional ... for their innovations and performance excellence. At that time its principle sponsor, ...
(Date:8/31/2015)... ... August 31, 2015 , ... In recent years, biodegradable ... as low carbon footprints and compostability. These properties can help in limiting the ... the basis of applications, the market for biodegradable plastics can be broadly segmented ...
Breaking Biology Technology:Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5
... provide human safety and, pharmacodynamic data,VANCOUVER, ... announce that its novel Innate Defense Regulator (IDR) IMX942 ... on April 27, 2009. The healthy volunteers were enrolled ... performed for Inimex in Montreal with the approval of ...
... compliance and persistence with chronic medications. Prescription refills increase up ... free service offers coaching, reminders and pharmacist support to alleviate ... - prescribed medication. , ... ...
... /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ... research organization (CRO) that provides design, development, and ... to many of the world,s leading pharmaceutical companies, ... the Second Annual Vaccine Industry Excellence Award for ...
Cached Biology Technology:Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator 2New Pleio Medication Adherence Service Increases Prescription Refills Up To 53% 2Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 2Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 3Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award 4
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... DURHAM, N.C. -- Obese people who consume increased amounts ... in particular in soft drinks and fruit juices, are ... more its more severe forms, fatty inflammation and scarring. ... they better understand what mechanism may account for fructose-related ...
... City, OK and Shenzhen, China -- May 2, 2012 ... in conjunction with George Mason University (GMU), the Massachusetts ... the University of Oklahoma Health Sciences Center (OUHSC), jointly ... 100 human adenoviruses gathered from researchers globally, including ones ...
... draws to an end. Guys drop dead by the hour, making ... to father their offspring. We,re often told that males are ... simple if you are a two-spotted goby, researchers from the Norwegian ... Two-spotted gobies are tiny fishes with a remarkable sex life ...
Cached Biology News:Increased fructose consumption may deplete cellular energy in patients with obesity and diabetes 2Increased fructose consumption may deplete cellular energy in patients with obesity and diabetes 3BGI, GMU, Mass. Eye and Ear and OUHSC announce agreement to sequence 100 human adenoviruses 2Desperate fishwives 2
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
...
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
Normal human AB serum, pooled...
Biology Products: